A5044576014- Acute Kidney Injury Research
- Chronic Kidney Disease and Diabetes
- Hepatitis C virus research
- Systemic Lupus Erythematosus Research
- Renal Diseases and Glomerulopathies
- HIV/AIDS drug development and treatment
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Dialysis and Renal Disease Management
- Wind and Air Flow Studies
- Liver Disease Diagnosis and Treatment
- HIV-related health complications and treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Atmospheric aerosols and clouds
- Hepatitis B Virus Studies
- Atmospheric chemistry and aerosols
- Vehicle emissions and performance
- Chronic Lymphocytic Leukemia Research
- Sepsis Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Meteorological Phenomena and Simulations
- Hemoglobinopathies and Related Disorders
- Air Quality and Health Impacts
- Kidney Stones and Urolithiasis Treatments
- Atmospheric and Environmental Gas Dynamics
- HIV/AIDS Research and Interventions
Medical Research Associates
2014-2024
Western University
2024
Oklahoma State University Oklahoma City
2024
University of Southern California
2016-2024
Piedmont International University
2024
California Institute of Technology
2024
Cincinnati Children's Hospital Medical Center
2012-2023
University of Cincinnati Medical Center
2002-2023
The University of Texas at Arlington
2023
University of Birmingham
2020
Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for whom treatment peginterferon is not an option, who have had a response to prior interferon treatment, currently no approved options. In phase trials, regimens including the oral nucleotide polymerase inhibitor sofosbuvir shown efficacy in patients HCV infection.We conducted two randomized, studies involving chronic infection. one trial, was option received and ribavirin (207 patients) matching placebo (71) 12...
The authors have previously shown that urine neutrophil gelatinase-associated lipocalin (NGAL), measured by a research ELISA, is an early predictive biomarker of acute kidney injury (AKI) after cardiopulmonary bypass (CPB). In this study, whether NGAL immunoassay developed for standardized clinical platform (ARCHITECT analyzer, Abbott Diagnostics Division, Laboratories, Park, IL) can predict AKI CPB was tested.In pilot study with 136 samples (NGAL range, 0.3 to 815 ng/ml) and 6 calibration...
Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited, the currently approved all‐oral regimens requiring 24‐week treatment and addition of ribavirin (RBV). This phase III study (ALLY‐3; ClinicalTrials.gov: NCT02032901) evaluated 12‐week regimen daclatasvir (DCV; pangenotypic nonstructural protein [NS]5A inhibitor) plus sofosbuvir (SOF; NS5B in infected 3. Patients were either naïve (n = 101) or experienced 51) received DCV 60 mg SOF 400 once‐daily 12...
Acute kidney injury (AKI) is a frequent complication of cardiopulmonary bypass (CPB). The lack early biomarkers has impaired our ability to intervene in timely manner. We previously showed small cohort patients that plasma neutrophil gelatinase-associated lipocalin (NGAL), measured using research enzyme-linked immunosorbent assay, an predictive biomarker AKI after CPB. In this study we tested whether point-of-care NGAL device can predict CPB larger cohort.First, cross-sectional pilot...
Several novel urinary biomarkers have shown promise in the early detection and diagnostic evaluation of acute kidney injury (AKI). Clinicians limited tools to determine which patients will progress more severe forms AKI at time serum creatinine increase. The prognostic utility traditional was evaluated during a prospective study 123 adults undergoing cardiac surgery.Urinary neutrophil gelatinase-associated lipocalin (NGAL), cystatin C (CyC), molecule-1 (KIM-1), hepatocyte growth factor...
Background & AimsAlthough hepatitis C virus (HCV) infection is common in patients with end-stage renal disease, highly efficacious, well-tolerated, direct-acting antiviral regimens have not been extensively studied this population. We investigated the safety and efficacy of ombitasvir co-formulated paritaprevir ritonavir, administered dasabuvir (with or without ribavirin) a prospective study stage 4 5 chronic kidney disease (CKD).MethodsWe performed single-arm, multicenter treatment-naïve...
Clinicians have access to limited tools that predict which patients with early AKI will progress more severe stages. In AKI, urine output after a furosemide stress test (FST), involves intravenous administration of (1.0 or 1.5 mg/kg), can the development stage 3 AKI. We measured several biomarkers in our previously published cohort 77 who received an FST and evaluated ability (n=25 [32.5%]), receipt RRT (n=11 [14.2%]), inpatient mortality (n=16 [20.7%]). With area under curve (AUC)±SEM...
Tolerance of the human kidney to ischemia is controversial. Here, we prospectively studied renal response clamp and reperfusion in humans, including changes putative biomarkers AKI. We performed biopsies before, during, after surgically induced 40 patients undergoing partial nephrectomy. Ischemia duration was >30 minutes 82.5% patients. There a mild, transient increase serum creatinine, but cystatin C remained stable. Renal functional did not correlate with duration. structural were much...
Importance A safe and effective treatment for recurrent Clostridioides difficile infection (CDI) is urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted microbiome, which promotes spore germination recurrence. Objectives To evaluate safety rate of CDI recurrence after administration investigational microbiome therapeutic SER-109 through 24 weeks. Design, Setting, Participants This phase 3, single-arm, open-label trial (ECOSPOR IV) was conducted at 72 US...
Abstract Objective To investigate the relationship of urinary biomarkers and established measures renal function to histologic findings in lupus nephritis (LN), test whether certain combinations above‐mentioned laboratory are diagnostic for specific features LN. Methods Urine samples from 76 patients were collected within 2 months kidney biopsy assayed lipocalin‐like prostaglandin D synthase (L‐PGDS), α 1 ‐acid glycoprotein (AAG), transferrin (TF), ceruloplasmin (CP), neutrophil...
Acute kidney injury (AKI) is a frequent complication of cardiopulmonary bypass (CPB). Serum creatinine (SCr), the current standard, an inadequate marker for AKI since delay occurs before SCr rises. Biomarkers that are sensitive and rapidly measurable could allow early intervention improve patient outcomes. We investigated value serum cystatin C as biomarker after pediatric CPB.We analyzed data from 374 prospectively enrolled children undergoing CPB. samples were obtained at 2, 12, 24 hours...
Background and objectives Novel urinary kidney damage biomarkers detect AKI after cardiac surgery using cardiopulmonary bypass (CPB-AKI). Although there is growing focus on whether leads to CKD, no studies have assessed novel remain elevated long term CPB-AKI. We was clinical or biomarker evidence of long-term injury in patients with Design, setting, participants, & measurements performed a cross-sectional evaluation for signs chronic both traditional measures population 372 potentially...
The inconsistent ability of novel biomarkers to predict acute kidney injury (AKI) across heterogeneous patients and illnesses limits integration into routine practice. We previously retrospectively validated the renal angina index (RAI) risk-stratify provide context for confirmatory serum biomarker testing prediction severe AKI.We conducted this first prospective study determine whether RAI on day admission (Day0) risk-stratified critically ill children 'persistent, AKI' Day 3 (Day3-AKI:...